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A novel fluorescein-bisphosphonate 
based diagnostic tool for the 
detection of hydroxyapatite in both 
cell and tissue models
Alisia M. Sim1,2,3, Nabil A. Rashdan2, Lin Cui2, Alastair J. Moss3, Fabio Nudelman  1, 
Marc R. Dweck3, Vicky E. MacRae2 & Alison N. Hulme  1
A rapid and efficient method for the detection of hydroxyapatite (HAP) has been developed which 
shows superiority to existing well-established methods. This fluorescein-bisphosphonate probe is highly 
selective for HAP over other calcium minerals and is capable of detecting lower levels of calcification 
in cellular models than either hydrochloric acid-based calcium leaching assays or the Alizarin S stain. 
The probe has been shown to be effective in both in vitro vascular calcification models and in vitro bone 
calcification models. Moreover we have demonstrated binding of this probe to vascular calcification 
in rat aorta and to areas of microcalcification, in human vascular tissue, beyond the resolution of 
computed tomography in human atherosclerotic plaques. Fluorescein-BP is therefore a highly sensitive 
and specific imaging probe for the detection of vascular calcification, with the potential to improve 
not only ex vivo assessments of HAP deposition but also the detection of vascular microcalcification in 
humans.
Calcium is a crucial intracellular element that is responsible for regulating many cellular processes across every 
cell type in biological organisms1. Calcium is found in either the free ion form or as a mineral phase, for example 
in the form of hydroxyapatite (HAP) that makes up bone and teeth. However mineralisation is also a critical com-
ponent of a wide range of diseases such cancer, arthritis and cardiovascular disease (CVD)2–4. In atherosclerosis 
the presence of microscopic deposits of HAP can weaken the fibrous cap of an atherosclerotic plaque, leading to 
rupture of the plaque and vessel occlusion5–9. In aortic stenosis the progressive accumulation of HAP in the valve 
leads to increasing obstruction to the flow of blood out of the heart, whilst in abdominal aortic aneurysm disease 
microcalcification is associated with aneurysms that expand more quickly and are at increased risk of rupture 
or requiring repair. Thus the development of a calcium assay which is able to selectively detect HAP with high 
sensitivity and specificity could both improve understanding of disease pathophysiology and aid the diagnosis of 
a range of clinical disorders including vascular calcification.
The most common assays for calcium phosphate mineralisation are calcium leaching by hydrochloric acid 
(HCl); and staining with Alizarin S and von Kossa stains10,11. Each comes with their own limitations. The calcium 
leaching assay is used in laboratory settings to determine the presence of calcification in vascular and bone cell 
models. The assay involves incubating cell monolayers in the presence of HCl which allows the extraction of free 
calcium ions from the cells. The calcium content is then detected using a colourimetric assay and normalised 
against the total number of cells per sample12. Given the timeframe of the calcium leaching assay (24–48 h) it 
is not suitable for high-throughput applications. The colourimetric stain Alizarin S detects calcium, and not 
phosphate, thus it can also bind to calcium-binding proteins and proteoglycans without discriminating for the 
presence of HAP13. Finally, the colourimetric von Kossa stain detects phosphates but only in acidic environments, 
even though the presence of phosphate does not necessarily imply the presence of calcium or even HAP10,13. Both 
Alizarin S and von Kossa stains are used to indicate calcium depositions but at best give only semi-quantitative 
calcium readings14. In this study, the fluorescein-bisphosphonate conjugate 1 (Fluorescein-BP, Fig. 1)15 was 
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repurposed to allow for a rapid and inexpensive method of studying calcification and its use was investigated in a 
range of cell based models as well as mouse and human vascular tissue.
Results
Fluorescein-BP synthesis and specificity. The bisphosphonate, alendronate is recognised as a bone tar-
geting reagent due to its striking ability to bind to HAP16,17. Previous experiments have shown that alendronate 
is readily able to bind to bulk calcium mineral even in the presence of free calcium ions; and it is approved for 
clinical use for Paget’s disease and osteoporosis16,18,19. The ready availability of the FDA-approved probe com-
ponents makes the alendronate-based Fluorescein-BP conjugate 1 particularly attractive for development and 
human translation as a method for the detection of calcification. Recently the Leong group reported the use of 
Fluorescein-BP 1 for the study of urinary calculi15; although the fluorescence intensity of the probe in the pres-
ence of macroscopic calcium oxalate (CaOx) was found to be relatively moderate.
Fluorescein-BP was synthesised following the procedure reported by the Leong group15. Specificity of the 
probe towards HAP was shown by incubating Fluorescein-BP with a range of calcium minerals including HAP, 
calcium pyrophosphate (CaPy), CaOx and calcium phosphate (CaPi). Aqueous suspensions of these minerals 
at fixed weight per volume were incubated with probe 1 for 2 hours, and un-bound probe was removed from 
the solids through a series of centrifugation and washing steps. Fluorescence analysis of the combined aqueous 
extracts allowed the levels of un-bound probe to be quantified and hence a direct comparison of the levels of 
Fluorescein-BP binding to each of the different calcium-containing minerals was enabled. These experiments 
showed that Fluorescein-BP demonstrated almost an order of magnitude higher selectivity towards HAP than 
any other calcium species tested (Fig. 1A). In contrast, when Alizarin S (2, Fig. 1) the most common histological 
stain for calcium, was incubated with the different calcium minerals it showed a very similar fluorescent intensity 
for each indicating non-specific binding (Fig. 1B). In order to achieve effective visualisation of the Alizarin S stain 
by fluorescence, millimolar concentrations of the stain were required which is in sharp contrast to the low micro-
molar concentrations required of probe 1. This reflects the relative brightness of the signal for each fluorophore 
which is proportional to its quantum yield (Φ = 0.79 for fluorescein20–22, and Φ = 0.001 for Alizarin S22,23).
Use of Fluorescein-BP in cell-based models of vascular calcification. A series of experiments were 
designed to probe the ability of the Fluorescein-BP probe 1 to define the location of HAP in cellular calcifica-
tion assays, exploiting both the selectivity and sensitivity which was demonstrated in the mineral-based assays. 
Vascular smooth muscle cells (VSMCs), the principal cell type involved in vascular calcification, can undergo 
a phenotypic transition under specific environmental conditions to calcifying osteoblastic cells24. The mouse 
VSMC line MOVAS-1 exhibits a smooth muscle cell phenotype and has been previously employed to investigate 
the VSMC cell cycle25. Validation of the Fluorescein-BP probe 1 was carried out using MOVAS-1 and primary 
mouse VSMCs.
Figure 1. Selectivity towards calcium minerals of Fluorescein-BP (1) in comparison to Alizarin S stain (2). 
Calcium minerals were incubated with Fluorescein-BP (5 μM) (A) or 1% w/w Alizarin S (B) in water for 
2 hours and the un-bound probe was removed and quantified. The histograms show the relative amounts of 
bound fluorophore for each of the calcium minerals. Data shown are representative of at least 3 independent 
experiments yielding comparable results. *P < 0.05, **P < 0.01, ***P < 0.001 compared to HAP, n = 6.
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Monolayers of MOVAS-1 cells were incubated with 2.4 mM Ca and 1.4 mM Pi for 7 days; then treated 
with Fluorescein-BP 1 for 2 h prior to imaging. Confocal microscopy (Fig.  2A–C) shows extracellu-
lar localisation of probe 1 (in green); indicative of the presence of HAP in the extracellular matrix in accord 
with previous reports26–29. In contrast, no signal was observed when the same cells were incubated with a 
fluorescein-amino-1-pentanol conjugate (SI Fig. 1); giving a clear indication that the bisphosphonate motif is 
responsible for Fluorescein-BP binding to HAP in a cellular environment. Raman spectroscopic analysis of the 
observed mineral deposits confirmed the presence of HAP, with its distinctive peak at 960 cm−1 (Fig. 2D)30.
To probe the range of conditions under which the Fluorescein-BP probe 1 can be used, and compare its 
efficacy with the hydrochloric acid-based calcium leaching assay and Alizarin S stain, a further series of calcifica-
tion assays were conducted using the MOVAS-1 cell line and primary mouse VSMCs. Monolayers of MOVAS-1 
cells were incubated in both phosphate-enriched (3.0 mM Pi; 5.0 mM Pi), and phosphate and calcium-enriched 
(2.4 mM Ca and 1.4 mM Pi; 2.7 mM Ca and 2.5 mM Pi), growth media. Both the hydrochloric acid-based cal-
cium leaching assay (4-fold, p < 0.001) (Fig. 3A) and the Fluorescein-BP 1 fluorescence assay (4-fold, p < 0.001) 
(Fig. 3B) show significant levels of calcium deposition in the presence of calcium-enriched media. The fluores-
cence assay (LOD 0.0065 µmol/L, SI Fig. 2) is able to detect the presence of HAP when using media enriched 
with only phosphate in comparison to the calcium leaching assay (LOD 225 µmol/L)31 demonstrating the greater 
sensitivity of Fluorescein-BP 1. A comparison of the fluorescence images obtained for well plates with images 
of Alizarin S staining of equivalent plates (Fig. 3C), shows that both fail to detect calcification in media only 
enriched with phosphate. However, when cells are incubated in the presence of both calcium and phosphate, 
the fluorescent probe is able to detect the deposition of microcrystalline HAP with greater sensitivity than the 
Alizarin S stain. This is particularly notable when the incubation media have been enriched with 2.4 mM Ca and 
1.4 mM Pi, as commonly used in vascular calcification models32.
When comparable studies were performed using primary mouse VSMCs (Fig. 4A–C), incubating the mon-
olayers with increasing levels of phosphate to induce calcification (1.8 mM Pi, 2.6 mM Pi and 3.0 mM Pi), the 
fluorescent probe (5-fold, p < 0.001) was also shown to be more sensitive than either the Alizarin S or calcium 
leaching assays (1.2-fold, p < 0.001).
In further experiments, MOVAS-1 cells (SI Fig. 3) and primary mouse VSMCs (SI Fig. 4) were incubated 
under standard calcification conditions (2.4 mM Ca and 1.4 mM Pi) and the calcification on days 3, 5 and 7 
Figure 2. Confocal Images showing dual staining and Raman spectra of MOVAS-1 monolayers. Monolayers 
of MOVAS-1 cells were grown to confluence (day 0) and then switched to calcification media (2.4 mM Ca and 
1.4 mM Pi) for 7 days, changing media on alternate days. The cell monolayers were treated sequentially with 
Fluorescein-BP (1 μM, 2 hours; green); CellMask Orange (500 nM, 10 minutes, pink); NBF (10%, 15 minutes); 
Triton X (0.05%, 3 × 5 minutes); DAPI (300 nM, 5 minutes, blue); then imaged on an Zeiss Confocal LSM710 
microscope (λex = 488 nm, 554 nm and 350 nm). Images are representative of at least 3 repeats. Scale 
bars = 100 µm. (A) Incubation with Fluorescein-BP and DAPI. (B,C) Incubation with Fluorescein-BP, CellMask 
Orange and DAPI. (D) Monolayers of MOVAS-1 cells were grown to confluence (day 0) on CaF2 slides and then 
switched to either control media or calcification media (2.4 mM Ca and 1.4 mM Pi) for 7 days, changing media 
on alternate days. The cell monolayers were fixed with NBF (10%, 15 minutes); and imaged using an InVia 
Renishaw Raman instrument (785 nm, 30 s, 50%). Following imaging, the cell monolayers were incubated with 
Alizarin S (2%, 10 minutes). Red dashed line indicates peak at 960 cm−1 for HAP while the black dashed line 
indicates the inherent cellular peak at 1003 cm−1 for phenylalanine. Images shown are representative of at least 3 
independent experiments yielding comparable results.
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was detected using Fluorescein-BP probe 1 (2.5-fold, p < 0.001 for MOVAS-1; 2.5-fold, p < 0.001 for VSMCs) 
and compared with calcium leaching using the hydrochloric acid-based assay (5-fold, p < 0.001 for MOVAS-1; 
2.5-fold, p < 0.001 for VSMCs) and staining by Alizarin S. The fluorescent probe was shown to be more sensitive 
than both the other assays. Similarly, when MC3T3 cells (SI Fig. 5), an osteoblast derived cell line which is com-
monly used for studies in the field of bone and skeletal mineralisation33,34, were incubated with Fluorescein-BP, 
calcium mineralisation was readily detected (2-fold, p < 0.001).
Ex vivo rat aorta and human tissue study. VSMC monolayer cultures are of only limited use in the 
study of calcification in CVD: they lack the architecture and matrix of normal vessels; they reach confluence over 
a short timeframe; they rapidly convert to a proliferative, secretory phenotype35; morphological variations have 
been seen at high passage numbers; and variations in the gene phenotype can also occur. Cultured aortae can 
provide complementary information that bridges the gap between traditional cell culture and animal models, 
under almost in vivo conditions35,36. Previous studies have cultured sectioned thoracic aortas dissected from mice 
and estimated the status of calcification under Pi stimulation at 2.6–3.0 mM Pi36; these phosphate concentrations 
correlate with myocardial infarction in human studies36.
Ex vivo aortic rings from rats were incubated under different calcification conditions (1.8 mM Pi, 2.6 mM 
Pi and 3.0 mM Pi) for 7 days and subsequently incubated with Fluorescein-BP 1 followed by Alizarin S (Fig. 5, 
SI Fig. 6). From both staining methods, it is apparent that with increasing calcification conditions there is an 
increase in signal in both the Alizarin S and Fluorescein channel. When the two channels are merged, it is clear 
Figure 3. Determination of calcification in the MOVAS-1 cell line at various concentrations (3.0 mM Pi, 
5.0 mM Pi, 2.4 mM Ca and 1.4 mM Pi, 2.7 mM Ca and 2.5 mM Pi). Monolayers of MOVAS-1 cells were grown 
to confluence (day 0) and then switched to calcification media. The monolayers were incubated in calcification 
media (3.0 mM Pi, 5.0 mM Pi, 2.4 mM Ca and 1.4 mM Pi, 2.7 mM Ca and 2.5 mM Pi) for 7 days, changing 
media on alternate days. (A) Calcium leaching assay: o-cresolphthalein complexone. (B) Fluorescence assay: 
cell monolayers were incubated with Fluorescein-BP (1 μM, 2 hours); NBF (10%, 15 minutes). (C) Fluorescence 
images and Alizarin S stain images: cell monolayers were either incubated with Fluorescein-BP (1 µM, 2 hours) 
and then fixed with NBF (10%, 15 minutes), or fixed with NBF (10%, 15 minutes) and then incubated with 
Alizarin S (2%, 500 μL, 10 minutes). Data shown in (A) and (B) are from at least 6 repeats and shown as the 
mean ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001 compared to control, n = 6. Images shown in (C) are 
representative of at least 3 independent experiments yielding comparable results. Arrows indicate the location 
of calcium deposits within the well. Scale bars = 250 μm.
www.nature.com/scientificreports/
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that the Alizarin S and Fluorescein-BP stains colocalize in most areas. No fluorescence signal is observed when 
the rings are cultured with control media confirming that the Fluorescein-BP probe is selective for HAP.
Next, a more detailed analysis of calcification in aortic rings was conducted using 5 µm sections (Fig. 6). 
Calcified rat aortic rings were fixed and cryosectioned on day 7; the sections were then incubated with 
Fluorescein-BP probe 1 followed by Alizarin S. Fluorescent microscopy of these sections confirms differences in 
calcification between the control and 3.0 mM Pi specimens. This also allows the location of the calcification to be 
determined; which in this rat model occurs in the medial layer of the aorta35.
PET/CT imaging using Na18F has been reported as a novel tool for vascular disease diagnosis9,37. Na18F is able 
to identify areas of micro-calcification that are associated with unstable plaque phenotype and which are beyond 
the resolution of CT. Indeed Na18F PET is currently being explored as a method for detecting high risk coronary 
plaques and improving cardiovascular risk prediction (clinicaltrials.gov NCT02278211)9,37,38. We next compared 
Fluorescein-BP binding to the detection of vascular calcification by computed tomography and Na18F PET in 8 
samples of human arterial tissues (7 affected by calcific atherosclerotic disease and 1 control tissue which was free 
of atherosclerosis). All the tissue samples were assessed initially using PET/CT scans followed by sectioning of 
the tissue as required to allow appropriate fluorescence images to be obtained (as depicted for a representative 
sample in Fig. 7, additional examples shown in SI Fig. 7). PET/CT imaging (Fig. 7A–C) showed both areas of 
macrocalcification, as detected by CT, and areas of microcalcification, as detected by PET using a Na18F tracer. 
Samples from both areas were sectioned and stained (Fig. 7D–K). The images show that Fluorescein-BP probe 
1 binds to both macro- and micro-calcification and colocalizes with Alizarin S staining (Fig. 7D,E). The control 
Figure 4. Determination of calcification in primary mouse VSMCs at various concentrations (1.8 mM Pi, 
2.6 mM Pi, 3.0 mM Pi). Monolayers of primary mouse VSMCs were grown to confluence (day 0) and then 
switched to calcification media. The monolayers were incubated in calcification media (1.8 mM Pi, 2.6 mM 
Pi, 3.0 mM Pi) for 7 days, changing media on alternate days. (A) Calcium leaching assay: o-cresolphthalein 
complexone. (B) Fluorescence assay: cell monolayers were incubated with Fluorescein-BP (1 μM, 2 hours); NBF 
(10%, 15 minutes). (C) Fluorescence images and Alizarin S stain images: cell monolayers were either incubated 
with Fluorescein-BP (1 µM, 2 hours) and then fixed with NBF (10%, 15 minutes) or fixed with NBF (10%, 
15 minutes) and then incubated with Alizarin S (2%, 500 μL, 10 minutes). Data shown in (A) and (B) are from 
at least 6 repeats and shown as the mean ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001 compared to control, 
n = 6. Images shown in (C) are representative of at least 3 independent experiments yielding comparable results. 
*P < 0.05, **P < 0.01, ***P < 0.001 compared to control, n = 6. Scale bars = 250 μm.
www.nature.com/scientificreports/
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tissue sample (Fig. 7L,M), where there was no clinical history of coronary disease, showed neither PET/CT signal 
nor fluorescence staining.
Discussion
Here, we demonstrate that Fluorescein-BP is a highly sensitivity and specific marker of HAP in vascular tis-
sue. Fluorescein-BP has been compared to the current gold standard techniques for identifying calcification, the 
Alizarin S and HCl decalcification assays, and in both instances shows greater sensitivity and selectivity for HAP. 
Moreover we have confirmed its binding to HAP in both in vitro cell models of vascular and bone calcification, 
ex vivo rat aorta tissue and human coronary atherosclerotic plaques. Given that its component parts are already 
FDA approved, Fluorescein-BP holds great translational potential for the detection of crystalline HAP in humans.
Vascular mineralisation in atherosclerotic plaques contains high concentrations of crystalline HAP39. Within 
the arterial walls, extracellular vesicles containing HAP are extruded from lipid-rich macrophages and apoptotic 
smooth muscle cells which increase the plaque structural stress and risk of fibroathermatous cap fracture40. The 
inflammatory milieu driving the production of HAP deposition is associated with a greater propensity to desta-
bilise plaques and results in clinical cardiovascular events41,42. Recent clinical trials have focused attention on the 
vital role that early calcification plays in carotid, aortic aneurysmal and coronary artery disease and hence there is 
a clinical imperative to better understand the mechanisms governing early calcification in the vascular wall41–43. 
The ability to differentiate calcium derivatives in regions of calcification, specifically by detecting HAP, will facili-
tate the dichotomisation of unstable and stable cardiovascular phenotypes in future clinical trials.
The detection of HAP deposition has been a field that has gained a lot of attention in the past 20 years1,44–46. 
Histological stains such as Alizarin S and von Kossa are widely used to study calcium deposits but their effective-
ness has been disputed since their binding modes are somewhat indiscriminate45. Additionally, calcein is a rou-
tinely used tool for imaging calcium, however, not only does it bind across a range of calcium species, but it is also 
non-specific for calcium and interacts with a range of other metals including aluminium and zinc47,48. Another 
recently reported probe used in animal based models of both bone and vascular disease is Osteosense (680 and 
750), a commercially available, near infrared (NIR) probe conjugated to a bisphosphonate49–51. However, the 
benefits offered by a NIR probe for in vivo studies, are off-set by the need for non-standard filters for plate readers 
and microscopes in laboratory based experiments which limited our capacity to directly compare the two probes.
Figure 5. Determination of calcification in rat aorta incubated under different calcification conditions (1.8 mM 
Pi, 2.6 mM Pi and 3.0 mM Pi). Rat aortic rings were incubated for 2 days in fresh control media followed by 
calcification media (1.8 mM Pi, 2.6 mM Pi and 3.0 mM Pi) for 7 days. The rings were subsequently incubated 
with Fluorescein-BP (1 µM, 2 hours), fixed with NBF (10%, 15 minutes), permeabilised in KOH (1%, 1 hour) 
and then incubated with Alizarin S (0.00005% Alizarin S in 1% KOH, 24 hours). Brightfield (A–E) Fluorescence 
(K–O) Alizarin S (F–J). Merged images (P–T) recorded using both Alizarin S and Fluorescein-BP channels. 
Images shown are representative of at least 3 independent experiments yielding comparable results. Scale 
bars = 250 µm.
www.nature.com/scientificreports/
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Fluorescein-BP probe 1, in comparison to Calcein and Osteosense, presents a more selective, sensitive and 
widely-applicable method of detecting calcification in vascular and bone models. In addition, the two low-cost 
reagents required for the synthesis of the probe are both commercially available, ensuring a wider user base for 
the new probe. Future in vivo studies might be enabled by intravascular administration of probe 1 using catheters 
fitted with a confocal endomicroscope probe, thus negating the need for conjugation to a costly NIR dye.
Conclusions
Fluorescein-BP probe 1 gives a dramatically improved signal output over more conventional imaging methods 
such as Alizarin S and von Kossa stains for the detection of calcium phosphate in a range of in vitro studies. It has 
been shown to be mineral-specific giving a markedly increased signal in the presence of HAP over other calcium 
species, and can be used in both condition-specific and temporal studies of calcification in cell-based models 
of CVD and bone disease. Staining with probe 1 is rapid, allowing high-throughput assays in multi-well format 
which are not possible with comparable assays such as the hydrochloric acid-based quantification method typi-
cally used in the field. When applied to ex vivo aortic sections and to human tissue presenting both macro- and 
micro-calcification, Fluorescein-BP 1 shows binding to both types of vascular calcification which are not readily 
detectable using one stand-alone technique. The employment of this probe may enable the elucidation of key 
mechanisms underpinning these pathological processes.
Figure 6. Determination of calcification in rat aortic ring sections. Rat aortic rings were incubated for 2 days in 
fresh control media followed by calcification media 3.0 mM Pi) for 7 days and fixed with NBF (10%, 15 minutes). 
Rings were cryosectioned into 5 μm sections. Sections were incubated with Fluorescein-BP (1 µM, 2 hours), 
permeabilised in KOH (1%, 1 hour), incubated with Alizarin S (0.00005% Alizarin S in 1% KOH, 24 hours), 
followed by DAPI (500 nM, 5 minutes). Brightfield (A,B) Fluorescence (E,F) Alizarin S (C,D). Merged images 
(G,H) recorded using Alizarin S, Fluorescein-BP and DAPI channels. Images shown are representative of at 
least 3 independent experiments yielding comparable results. Scale bars = 250 µm.
www.nature.com/scientificreports/
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Methods
Unless otherwise noted, starting materials and reagents were obtained from Sigma-Aldrich and were used with-
out further purification. Saturated aqueous solutions of inorganic salts are represented as (volume, sat. aq.). 
Figure 7. Determination of calcification in human vascular tissue (calcified and control). (A) Volume rendered 
image; (B) CT image; (C) PET image, with NaF tracer, of vascular tissue. Yellow, purple and orange boxes 
indicate the areas selected for tissue sectioning where Brightfield and Fluorescence images of calcification were 
taken. (D–G) Brightfield and Fluorescence (Alizarin S, Fluorescein-BP, DAPI) images of tissue in the yellow box 
which show high CT activity. (H–K) Brightfield and Fluorescence (Alizarin S, Fluorescein-BP, DAPI) images 
of tissue in the purple box which show high PET activity. Sections were incubated with Fluorescein-BP (1 μM, 
2 hours), Alizarin S (2%, 10 minutes) and DAPI (500 nM, 5 minutes) and subsequently imaged. Black boxes 
indicate region of Brightfield image where Fluorescence images were taken. Control sample, PET image (L) and 
Fluorescence (Alizarin S, Fluorescein-BP and DAPI, M). Scale bars = 2.0 mm for Brightfield and 100 µm for 
Fluorescence.
www.nature.com/scientificreports/
9ScienTific RepoRts |         (2018) 8:17360  | DOI:10.1038/s41598-018-35454-9
Semi-preparative RP-HPLC was performed using a Waters 600E pump, a Waters 486 tuneable absorbance detec-
tor controlled by Water Empower software which was equipped with a Phenomenex Luna C18(2), 5 µm particle 
size, 250 × 21.2 mm column at a flow rate of 18 mL min−1.
1H and 13C NMR spectra were obtained on Bruker AVA600 instrument at the stated frequency using TMS 
as a reference and residual solvent as an internal standard. Infra-red spectra were recorded neat on a Shimadzu 
IRAffinity-1. Electrospray (ESI) mass spectra were obtained on a Bruker micrOTOF II instrument. UV/VIS 
absorption spectra were measured using a Shimadzu UV-1800 spectrometer. Melting points were determined 
on a Gallenkamp Electrothermal Melting Point apparatus and are uncorrected. Fluorescence data was obtained 
using SPEX Fluoromax-3.
Fluorescein-BP conjugate (1). Sodium alendronate (34 mg, 1 mmol, 5 eq; Alfa Aesar) was dissolved in 
NaHCO3 (1 mL, sat. aq.). Fluorescein (5/6) NHS ester (10 mg, 0.2 mmol, 1 eq; Thermo Fisher) dissolved in DMF 
(0.1 mL) was added to the solution and the reaction mixture was stirred for 2 days at room temperature in the 
dark. The solution was acidified with TFA (10% v/v aq.) and purified by RP HPLC [isocratic 80/20 H2O (+0.1% 
v/v TFA)/MeCN (+0.1% v/v TFA)] to yield the fluorescein-BP conjugate as an orange solid (34 mg, 50%).
λabs/λem 491/515; Φ 0.83; ε 41,400 M−1cm−1; MP 240 °C; IR (solid, cm−1) 1700 (C=O), 1635 (C=O), 1538 
(N-H), 1271 (P=O), 1116 (C-N); 1H NMR (601 MHz, DMSO-d6) δ 10.13 (2 H, br s, OH isomer 1 + 2) 8.85 (0.6 H, 
t, J = 5.7 Hz, NH isomer 1), 8.72 (0.4 H, t, J = 5.9 Hz, NH isomer 2), 8.47 (0.6 H, d, J = 1.5 Hz, ArH isomer 1), 8.26 
(0.6 H, dd, J = 8.0, 1.5 Hz, ArH isomer 1), 8.19 (0.4 H, dd, J = 8.1, 1.4 Hz, ArH isomer 2), 8.07 (0.4 H, d, J = 8.1 Hz, 
ArH isomer 2), 7.70 (0.4 H, s, ArH isomer 2), 7.37 (0.6 H, d, J = 8.0 Hz, ArH isomer 1), 6.69 (2 H, dd, J = 5.3, 2.3 Hz, 
ArH isomer 1 + 2), 6.63 – 6.53 (4 H, m, ArH isomer 1 + 2) 3.30 (1.2 H, q, J = 6.5 Hz, NCH2 isomer 1), 3.17 (0.8 H, 
q, J = 6.4 Hz, NCH2 isomer 2), 2.01-1.70 (4 H, m, CH2CH2 isomer 1 + 2); 13C NMR (151 MHz, DMSO-d6) δ 168.69 
(C=O), 168.55 (C=O), 164.86 (C=O), 164.67 (C=O), 160.06 (2 × Ar C), 155.02 (Ar C), 153.17 (Ar C), 152.32 
(2 × Ar C), 152.30 (2 × Ar C), 141.35 (Ar C), 136.96 (Ar C), 135.16 (Ar CH), 129.85 (ArCH), 129.74 (2 × ArCH), 
129.66 (2 x ArCH), 128.55 (Ar C), 126.92 (Ar C), 125.27 (Ar CH), 124.66 (Ar CH), 123.72 (Ar CH), 122.73 
(Ar CH), 113.21 (2 x Ar CH), 113.16 (2 x Ar CH), 109.67 (2 × Ar C), 109.60 (2 × Ar C), 102.73 (2 × Ar CH), 
83.75 (C), 83.72 (C), 72.60 (t, 1JCP = 148 Hz, C), 41.99 (t, 2JCP = 21 Hz, CH2), 41.65 (t, 2JCP = 21 Hz, CH2), 31.13 
(CH2), 24.06 (CH2); m/z (ESI+, H2O:MeOH): 630 ([M+Na]+, 10%), 608 ([M+H]+, 100); 31P NMR (202 MHz, 
DMSO-d6) δ 20.21.
Fluorescein-BP and Alizarin S incorporation in Calcium minerals. Aqueous suspensions of calcium 
species (HAP, CaOx, CaPi, CaPyr, Sigma and Fisher Scientific) (50 mg) were incubated with Fluorescein-BP 1 
(5 µM) for 2 hours. Unbound probe was removed by centrifugation of the suspension at 670 g for 5 minutes, the 
supernatant was removed and the precipitated solid was resuspended in water with continuous agitation for 
15 minutes. This process of centrifugation and resuspension was repeated three times, until there was no further 
fluorescence in the supernatant after centrifugation. Fluorescence analysis of the combined aqueous extracts was 
performed using a Synergy HT Multi Mode Microplate reader at 488 nm.
VSMC isolation and culture. Primary aortic VSMCs were isolated from five week old C57BL/6 mice 
(Charles River Laboratories) as previously described1,52,53. Mice were euthanized by cervical dislocation, the aorta 
was then dissected and the adventitia removed. After washing with Hanks’ balanced salt solution (HBSS; Life 
Technologies), the aorta was cut longitudinally to expose the endothelial layer. Eight aortae were pooled together 
and incubated for 10 minutes at 37 °C in 1 mg/mL trypsin (Life Technologies) to remove any remaining adventitia 
and endothelium. Aortae were washed and incubated overnight at 37 °C in VSMC growth medium containing 
Minimum Essential Medium Eagle alpha modification (α-MEM; Life Technologies), 10% foetal bovine serum 
(FBS; Life Technologies) and 1% gentamicin (Life Technologies) in a humidified 5% CO2 incubator. Tissues were 
then washed and incubated in 425 UI/mL collagenase type II (Worthington Biochemical Corporation) for 4 hours 
at 37 °C. The resulting cell suspension was centrifuged at 320 g for 5 minutes. VSMC pellets were resuspended in 
culture medium and cultured for two passages in T25 tissue culture flasks (Corning) coated with 0.25 μg/cm2 
laminin (Sigma) to promote maintenance of the contractile differentiation state54.
MOVAS-1 culture. MOVAS-1 cells (ATCC) were suspended in growth media consisting of Dulbecco’s 
Modified Eagle Media (DMEM)-Formula 12 (Life Technologies) supplemented with 10% FBS and 1% gentamicin 
and cultured at 37 °C, in the presence of 5% CO2. Before experimentation, MOVAS-1 were expanded in growth 
media and cells were then used for experiments.
Induction of calcification in MOVAS-1 and VSMCs. Calcification was introduced as previously 
described1,32,53. In brief, for MOVAS-1, cells were grown to confluence (day 0) and switched to calcification 
medium, which was prepared by adding 1 M inorganic phosphate (mixture of NaH2PO4 and Na2HPO4, pH = 7.4) 
and 1 M CaCl2 to reach a final concentrations of 3.0 mM Pi, 5.0 mM Pi, 2.4 mM Ca and 1.4 mM Pi or 2.7 mM Ca 
and 2.5 mM Pi. For VSMCs, cells were grown to confluence (day 0) and switched to calcification medium, which 
was prepared by adding 1 M inorganic phosphate to reach a final concentrations of 1.8 mM Pi, 2.6 mM Pi and 
3.0 mM Pi. Cells were incubated for 7 days in 95% air/5% CO2, changing media on alternate days.
Fluorescence staining of fixed cells using Fluorescein-BP and CellMask Orange Plasma Membrane 
Stain. MOVAS-1 cells were grown on glass coverslips and calcified as described above. After incubation with 
Fluorescein-BP probe 1 (1 μM) for 2 hours, the media was changed, the monolayer was washed twice with HBSS and 
fresh HBSS containing 500 nM CellMask Orange Plasma Membrane Stain (Thermo Fisher) was added for 10 min-
utes. The monolayer was washed with phosphate buffered saline (PBS, 2×) and water (1×), fixed with 10% neu-
tral buffered formalin (NBF) for 15 minutes and washed with PBS (2×) and water (1×). The cell monolayers were 
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permeabilised with Triton X-100 (0.05%, 3×) for 5 minutes and incubated with DAPI (300 nM; Life Technologies) 
for 5 minutes. Excess DAPI was removed by washing with water (1×). Glass coverslips were mounted onto slides 
with Prolong Gold Anti-Fade Reagent (Life Technologies). Fluorescence signal was detected under a Zeiss Axiovert 
25 inverted microscope and/or Zeiss Confocal LSM 710 at 488 nm (Fluorescein-BP), 554 nm (CellMask Orange) 
and 350 nm (DAPI).
Raman microscopy. MOVAS-1 were grown and calcified (2.4 mM Ca and 1.4 mM Pi) on CaF2 slides. After 
7 days, the monolayer was fixed with 10% NBF for 15 minutes. Raman imaging was carried out using an InVia 
Renishaw Microscope with laser excitation at 785 nm and a 50, N.A. 0.75 objective. The total data acquisition was 
performed during 30 s for spectra with a 50% laser power using the WiRE software. All of the spectra acquired 
were background subtracted using a background correction algorithm in the WiRE software.
Fluorescence microscopy. MOVAS-1 and VSMCs were grown on plates and calcified as described above. 
Media was removed and the cell monolayer was subsequently washed with HBSS then incubated with DMEM/
F12 (MOVAS-1) and α-MEM (VSMCs) containing Fluorescein-BP probe 1 (1 μM) for 2 hours. The media was 
then extracted and the cell monolayer was washed twice with HBSS, fixed with 10% NBF for 15 minutes and 
washed with PBS (PBS, 2×) and water (1×). Fluorescence images were captured using a Leica DMBL-2 upright 
fluorescent microscope and on Synergy HT Multi Mode Microplate reader at 488 nm (Fluorescein-BP).
Calcium leaching assay. Calcium deposition was quantified as previously described32,52. Briefly, cells were 
rinsed with phosphate buffered saline (PBS) and decalcified with 0.6 N HCl at room temperature for 24 hours. 
Free calcium was determined calorimetrically by a stable interaction with o-cresolphthalein complexone using 
a commercially available kit (Randox Laboratories Ltd.) and corrected for total protein concentration (Bio-Rad 
Laboratories Ltd).
Alizarin S staining of cell monolayers. Cells were grown in plates and calcified as described above. Media 
was removed and the cell monolayer was subsequently washed with HBSS. Cells were fixed in 10% NBF for 
15 minutes before washing twice with PBS. The cells were then stained with Alizarin S (2%, pH 4.2; 500 µL) for 
10 minutes at rt. The supernatant was discarded and the cell monolayer was washed with water (3×) and then 
imaged at 530 nm (Alizarin S).
Ex vivo aorta isolation and culture. Aortic rings were dissected from eight week old Fischer male rats. 
Rats were euthanized by cervical dislocation, the aorta was then dissected and the adventitia removed. After 
washing with HBSS the aortae were cut into ~4 mm thick rings and cultured in α-MEM supplemented with 
10% FBS and 1% gentamicin at 37 °C in 95% air/5% CO2. After 1 day, the media was changed to calcifying media 
(1.8 mM Pi, 2.6 mM Pi, 3.0 mM Pi) for 7 days, changing media on alternate days. On day 7, aortas were incubated 
with Fluorescein-BP (1 µM) for 2 hours. Aortas were washed with PBS (2×) and fixed with 10% NBF for 15 min-
utes. Residual NBF was removed by washing with PBS (2×) and water (1×). For Alizarin S staining, the fixed 
aortas were permeabilised with 1% KOH for 1 hour followed by overnight staining with 0.00005% Alizarin S in 
1% KOH. Residual Alizarin S was removed by washing with water (3×). Rings were then imaged under a Zeiss 
Axiovert 25 inverted microscope at 488 nm (Fluorescein-BP) and 530 nm (Alizarin S).
Aortic sections. Aortic rings were dissected and calcified following the standard protocol. Once calcified, the 
rings were fixed in 10% NBF for 15 minutes and then cryosectioned into 5 μm thick sections. Sections were then 
imaged under a Leica DMBL-2 upright fluorescent microscope at 488 nm (Fluorescein-BP), 530 nm (Alizarin S) 
and 350 nm (DAPI).
Human tissue. Atherosclerotic layers of left main coronary arteries were analysed from a range of patients, 
both male and female between the age of 48–71, for which main cause of death was either haemopericardium or 
ischaemic and hypertensive heart disease. Upon approval, the tissue was frozen at −80 °C.
PET/CT analysis of human tissue. Thawed non-decalcified coronary artery specimens were incubated 
for 20 minutes in 18F-sodium fluoride 100 kBq/mL solution (10.5 MBq 18F-NaF in 99.5 mL 0.9% NaCl). Samples 
were twice washed in 10 mL 0.9% NaCl for 5 minutes to remove unbound 18F-fluoride. Coronary artery spec-
imens were scanned using high-resolution micro-positron emission tomography and non-contrast computed 
tomography [50 kV p tube voltage, 300 ms exposure time] (Mediso nanoScan PET/CT). After whole specimen 
imaging, the coronary arteries were fixed in 10% buffered formaldehyde before being dehydrated, embedded in 
paraffin wax and sectioned (5 μm thickness).
Alizarin S Staining of human tissue. Sections were de-waxed in xylene and stained with 2% Alizarin S for 
5 minutes, washed three times with water and dehydrated to visualize calcium deposition. Images were obtained 
using a Nikon Ni1 Brightfield microscope.
Fluorescein-BP and Alizarin S Staining of human tissue. Sections were de-waxed in xylene and incu-
bated with Fluorescein-BP probe 1(1 µM) for 2 hours, washed in water (2×) followed by incubation with 2% 
Alizarin S (250 µL) for 5 minutes. Sections were washed in water (3×) and subsequently incubated with DAPI 
(500 nM) for 5 minutes. Sections were washed with water (1×) and then mounted using ProLong Gold Antifade. 
Fluorescence signal was detected using a Leica DMRB fluorescence microscope at 488 nm (Fluorescein-BP), 
530 nm (Alizarin S) and 350 nm (DAPI).
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Statistical analysis. Two-sample Student’s t-test was used to analyse the significance between data sets. 
Data are presented as mean ± standard error of the mean (S.E.M.). All statistical analysis was performed using 
Minitab 17 (Minitab Inc.). p < 0.05 was considered to be significant, and p-values are represented as: *p < 0.05; 
**p < 0.01; ***p < 0.001.
Ethical approval. All animal experiments were approved by The Roslin Institute’s Animal Users Committee 
and the animals were maintained in accordance with Home Office guidelines for the care and use of labora-
tory animals. Atherosclerotic layers of left main coronary arteries were obtained from victims of sudden death 
at autopsy with written informed relative authorisation from the next of kin. Ethical approval was granted by 
National Health Service Research Ethics Committee South East Scotland (14/SS/1090). The retention, storage 
and use of tissue sections were compliant with the United Kingdom Human Tissue Act of 2004 and in accordance 
with the relevant guidelines and regulations approved by National Health Service Research Ethics Committee 
South East Scotland (14/SS/1090).
Data Availability
All data generated and analysed during this study are available as Supplementary Data online. Primary data files 
are available at https://doi.org/10.7488/ds/2467.
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